NCT07212322 - A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 10, 2025

Primary Completion Date

May 20, 2027

Study Completion Date

July 20, 2027

Conditions

Systemic Lupus ErythematosusIdiopahic Inflammatory MyopathiesAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisSjögren's SyndromeAntiphospholipid SyndromeImmune ThrombocytopeniaSystemic Sclerosis

Interventions

DRUG

CD19 UCAR-T cells

CD19 UCAR-T cells treatment

Trial Locations (1)

300020

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER